INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09969 INNOCARE

Market Closed 08-07 16:08:13

14.300

+0.500

+3.62%

High14.510	Low13.720	Vol11.30M
Open13.800	D1 Closing13.800	Amplitude5.72%
Mkt Cap25.27B	Tradable Cap21.36B	Total Shares1.77B
T/O159.93M	T/O Rate0.76%	Tradable Shares1.49B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"INNOCARE","latestPrice":14.3,"timestamp":1786090093009,"preClose":13.8,"halted":0,"volume":11299999,"delay":0,"changeRate":0.036231884057971016,"floatShares":1494000000,"shares":1767000000,"eps":0.38,"marketStatus":"Market Closed","change":0.5,"latestTime":"08-07 16:08:13","open":13.8,"high":14.51,"low":13.72,"amount":159929539,"amplitude":0.057246,"askPrice":14.3,"askSize":41000,"bidPrice":14.29,"bidSize":26000,"shortable":3,"etf":0,"ttmEps":0.469,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786325400000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":13.8,"openAndCloseTimeList":[[1786066200000,1786075200000],[1786078800000,1786089600000]],"volumeRatio":1.716322514111461,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"Innocare Pharma Limited","latestPrice":29.08,"timestamp":1786086000000,"preClose":27.35,"halted":0,"volume":11955800,"delay":0,"premium":"-57.73"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2657612460","title":"InnoCare Pharma (SEHK:9969) Following Breakthrough Therapy News And The Undervalued Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612460","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657612460?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:42","pubTimestamp":1786081373,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) is back in focus after China’s NMPA granted Breakthrough Therapy Designation to its orelabrutinib and mesutoclax combination for previously treated marginal zone lymphoma, following strong clinical data shared at ASCO 2026.\nSee our latest analysis for InnoCare Pharma.\nThe Breakthrough Therapy Designation sits against a share price of HK$13.8, with a year to date share price return of 10.4% and a three year total shareholder return of 97.14%, even though the one...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-following-breakthrough-therapy-news","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-following-breakthrough-therapy-news","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198615330","title":"InnoCare Issues 2.04 Million A-Shares Under Incentive Plan, Lifting Total Outstanding to 1.77 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1198615330","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198615330?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:07","pubTimestamp":1785924424,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Limited reported its Monthly Return for July 2026, showing a marginal uptick in outstanding shares driven by restricted-share incentives, while its authorised capital and Hong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655286778","title":"Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655286778","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655286778?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:15","pubTimestamp":1785323717,"startTime":"0","endTime":"0","summary":"In July 2026, InnoCare Pharma reported that its oral TYK2 allosteric inhibitor fadeucravacitinib (ICP-488) met the primary endpoint with statistically significant, clinically meaningful benefits and a consistent safety profile in a registrational Phase III trial for adults with moderate-to-severe plaque psoriasis.\nThis success further underscores InnoCare’s push into oral TYK2 therapies across multiple autoimmune skin diseases, potentially broadening its late-stage dermatology portfolio...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/breakthrough-psoriasis-data-for-oral-tyk2-drug-might-change","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/breakthrough-psoriasis-data-for-oral-tyk2-drug-might-change","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARTY","VTHR","BK1161","AIPO","QTOC","BK1574","CHAT","09969","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654073308","title":"InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2654073308","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654073308?lang=en_us&edition=fundamental","pubTime":"2026-07-28 13:10","pubTimestamp":1785215442,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","09969","III","BK4134","BK1161","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179520655","title":"Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1179520655","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179520655?lang=en_us&edition=fundamental","pubTime":"2026-07-28 07:44","pubTimestamp":1785195867,"startTime":"0","endTime":"0","summary":"Seven government departments have issued the \"15th Five-Year Plan for Disease Prevention and Control.\" The plan prioritizes the prevention and control of major infectious diseases, adopting a...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1237","IE0008369823.USD","LU0140636845.USD","BK1161","SKHX","BK1191","LU1226287529.USD","LU1226288253.USD","LU1993786604.SGD","BK1587","07709","LU1807302812.USD","FRHC","LU0072913022.USD","IE00BZ08YT58.USD","BK1564","IE0008368742.USD","HYNX","LU1152091168.USD","LU0314109678.HKD","BK1515","01093","LU1226287792.SGD","IE00B543WZ88.USD","SKDD","LU0067412154.USD","DRAL","SK","IE00B5MMRT66.SGD","LU0880133367.SGD","BK1212","09971","BK1163","LU1226287875.USD","LU0315179316.USD","LU1152091754.HKD","EEMO","LU1951186391.HKD","LU1960683339.HKD","IE00B031HY20.USD","KCE","LU0501845795.SGD","BK4588","BK4585","SG9999004220.SGD","SKHZ","SKUU","KURE","REDS","06181","BK1227","SGXZ90724238.SGD","BK1147","KCAI","LU1226288170.HKD","SKHYV","LU1008478684.HKD","HK0000165453.HKD","IPOS","VXUS","03958","LU0326950275.SGD","SKHU","RAM","09969","EDZ","BK4127","LU2039709279.SGD","SG9999001051.SGD","SKHY","LU1328277881.USD","BK1574","LU1813983027.USD","IE00BZ08YR35.GBP","09858","BK1544","IE00BZ08YS42.EUR","BK1521","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154417308","title":"Movement Alert｜InnoCare Pharma Falls 5.04% in Regular Trading, Biotech Sector Sell-Off Compounds Post-Catalyst Profit-Taking","url":"https://stock-news.laohu8.com/highlight/detail?id=1154417308","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154417308?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:55","pubTimestamp":1784256903,"startTime":"0","endTime":"0","summary":"On July 17, InnoCare Pharma declined 5.04% in regular trading, trading at HK$13.88/share, with turnover of HK$85.67 million.The decline comes as the broader biotechnology sector experienced a sharp...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651457384","title":"InnoCare Pharma's Phase II Study of Vitiligo Drug Shows Consistent Safety, Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2651457384","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651457384?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:46","pubTimestamp":1784198815,"startTime":"0","endTime":"0","summary":"InnoCare Pharma's  phase II portion of the ongoing phase II/III adaptive study of soficitinib met its primary endpoint.The drug showed meaningful improvements versus placebo for the treatment of adult patients with non-segmental vitiligo, according to a Thursday Hong Kong bourse filing.Treatment with the drug also demonstrated consistent efficacy across multiple secondary endpoints.The drug's safety profile is consistent with previous studies.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","09969","688428","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119468233","title":"Innocare's TYK2 Inhibitor Soficitinib Meets Primary Endpoint in Phase II Vitiligo Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1119468233","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119468233?lang=en_us&edition=fundamental","pubTime":"2026-07-16 16:47","pubTimestamp":1784191679,"startTime":"0","endTime":"0","summary":"Clinical trial results for Innocare Pharma Limited (ASX: 688428) show its investigational drug has successfully achieved its primary objective in a mid-stage study.The company announced that the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","09969","BK0239","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136106160","title":"Phase III Trial for Innocare's Atopic Dermatitis Drug Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1136106160","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136106160?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:03","pubTimestamp":1784113416,"startTime":"0","endTime":"0","summary":"Innocare has announced that its internally developed, novel oral tyrosine kinase 2 (TYK2) inhibitor, soficitinib (ICP-332), has successfully met the primary endpoint in its Phase III registration...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","BK1574","BK1161","09969","688428","III","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137000476","title":"Movement Alert｜InnoCare Pharma Rises 5.09% in Regular Trading, Biotech Sector Rallies as CDH17 ADC Clinical Data Published","url":"https://stock-news.laohu8.com/highlight/detail?id=1137000476","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137000476?lang=en_us&edition=fundamental","pubTime":"2026-07-15 09:57","pubTimestamp":1784080661,"startTime":"0","endTime":"0","summary":"On July 15, InnoCare Pharma rose 5.09% in regular trading, trading at HK$15.04 per share, with turnover of HK$67.34 million.The gain was driven by a broad-based rally in the biotech sector alongside...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651973109","title":"InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2651973109","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651973109?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:31","pubTimestamp":1784021502,"startTime":"0","endTime":"0","summary":"In July 2026, InnoCare Pharma reported that it had dosed the first patient in a Chinese clinical trial of ICP-B208, a novel in-house CDH17-targeted antibody-drug conjugate (ADC) designed with a proprietary payload and protease-cleavable linker for improved stability and safety.\nThis marks an early but important test of InnoCare’s ADC platform against CDH17, a tumor-restricted target relevant to multiple gastrointestinal cancers for which no CDH17 ADCs are yet approved globally.\nNext, we’ll...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-is-up-66-after-first-cdh17-adc-ente","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-is-up-66-after-first-cdh17-adc-ente","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADC.AU","BK4080","09969","BK1574","BK1161","BK4231","BK7095","ADC","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650580711","title":"Is InnoCare Pharma (SEHK:9969) Undervalued On Its Breakthrough Lupus Trial Results?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650580711","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650580711?lang=en_us&edition=fundamental","pubTime":"2026-07-11 05:34","pubTimestamp":1783719282,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) is back in focus after new clinical data showed its BTK inhibitor orelabrutinib was well tolerated and clinically effective in a large Phase IIb study for systemic lupus erythematosus.\nSee our latest analysis for InnoCare Pharma.\nAlongside the positive lupus data, InnoCare Pharma has also started dosing patients in China with its CDH17 targeted ADC ICP-B208. The stock’s recent momentum reflects this, with a 1 month share price return of 34.55% but a 1 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-innocare-pharma-sehk9969-undervalued-on-its-breakthrough","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-innocare-pharma-sehk9969-undervalued-on-its-breakthrough","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159004783","title":"Movement Alert｜InnoCare Pharma Rises 5.07% in Regular Trading, HK Innovative Drug Sector Rallies as ADC Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=1159004783","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159004783?lang=en_us&edition=fundamental","pubTime":"2026-07-10 11:18","pubTimestamp":1783653506,"startTime":"0","endTime":"0","summary":"On July 10, InnoCare Pharma rose 5.07% in regular trading, trading at HKD 14.06/share, with turnover of approximately HKD 74.04 million.On the news front, Hong Kong-listed innovative drug stocks...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133667142","title":"Innocare Pharma Shares Advance with Robust Quarterly Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1133667142","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133667142?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:40","pubTimestamp":1783597243,"startTime":"0","endTime":"0","summary":"The stock of Innocare Pharma Limited (ASX: 688428) closed higher today.At the time of writing, Innocare Pharma Limited (ASX: 688428) closed at 29.10 yuan, marking a gain of 4.49%. Trading volume...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK0239","688428","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188490022","title":"Hong Kong Market Closes Higher, Healthcare and Tech Stocks Lead Gains While AI Hardware Sector Plunges","url":"https://stock-news.laohu8.com/highlight/detail?id=1188490022","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188490022?lang=en_us&edition=fundamental","pubTime":"2026-07-06 16:54","pubTimestamp":1783328072,"startTime":"0","endTime":"0","summary":"Hong Kong's stock market advanced in a choppy session on Friday, with all three major indices rising more than 1% at their intraday highs.The Hang Seng Index closed up 1.14% or 266.29 points at...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008368411.USD","LU0856984785.SGD","BK1586","QTOC","LU1794554557.SGD","SG9999015986.USD","LU0054237671.USD","LU0326948709.USD","LU1769817179.HKD","LU0315179316.USD","LU0345776255.USD","LU1831875114.USD","LU1868838027.USD","LU0164872284.USD","LU0106252389.USD","LU0823397103.USD","LU2237443622.USD","LU0823413587.USD","LU0572939691.SGD","BK1553","SG9999006514.SGD","SGXZ31699556.SGD","LU2237443895.HKD","LU0642271901.SGD","09939","LU0049853897.USD","LU2133065610.SGD","LU1008478684.HKD","LU0488056044.USD","LU0561508036.HKD","LU2242644610.SGD","CXSE","HK0000320264.USD","LU0882747503.HKD","LU0577902538.SGD","LU0786609619.USD","LU0149721374.USD","LU0675040207.SGD","SG9999002562.SGD","LU0244354667.USD","HK0000306685.HKD","LU0588545730.USD","LU0414403682.SGD","IE00BZ08YS42.EUR","BKF","02419","SOCL","SGXZ81514606.USD","LU0287142896.SGD","LU0345769128.USD","LU0417516571.SGD","LU0828238088.HKD","LU1720050803.USD","07200","LU0384037296.USD","LU0898667661.SGD","LU0821914370.USD","LU0132412106.USD","LU0886674414.USD","LU0449509016.USD","LU0320764599.SGD","LU0456827905.SGD","LU2498475776.HKD","LU1023057109.AUD","LU0096374516.USD","LU0509642566.USD","LU0229945570.USD","LU0328353924.USD","CHAT","LU0175139822.USD","IE0003795394.USD","LU0594300179.USD","LU0196878994.USD","LU0048388663.USD","IE0003895053.USD","LU1251922891.USD","LU1733274473.HKD","LU1102505929.USD","LU0047713382.USD","LU1226287875.USD","SG9999001051.SGD","LU0594300419.USD","FPA","LU1481107354.HKD","IE0003851619.USD","LU1051768304.USD","LU1725190679.HKD","IE0008368742.USD","LU0164865239.USD","LU0293314216.USD","LU0348816934.USD","IE00B97KM107.HKD","LU0455707207.USD","LU1226288253.USD","IE0031814852.USD","BK1591","LU2097828805.USD","LU0070217475.USD","LU1515016050.SGD","SG9999013353.USD","FDNI","ESPO","HK0000306701.USD","IE00B0169L03.USD","LU1323998911.USD","LU0700851271.USD","LU1051769294.HKD","LU1956131251.USD","BIDD","BK1610","BK1516","BK1515","LU2039709279.SGD","SG9999006597.SGD","LU0348788117.USD","SG9999002463.SGD","LU0708995153.HKD","LU0738912210.USD","MCHmain","BK4585","LU0865486749.SGD","IE00BQXX3C00.GBP","LU0072913022.USD","LU0307460666.USD","LU1282651048.USD","LU2237443382.USD","LU2362541513.USD","IE00B031J352.USD","LU0541502299.USD","LU1328615791.USD","LU0683595622.HKD","LU0648948544.HKD","IE00B067MR52.USD","LU0348723411.USD","LU2294711473.HKD","IE00BPRC5H50.USD","LU1048484197.HKD","LU0588545490.SGD","LU0054450605.USD","SG9999014880.SGD","IE00BGV7N243.SGD","JEMA","LU1328277881.USD","LU1366334651.USD","IE00BZ08YR35.GBP","LU1691799644.USD","LU3063872942.SGD","HK0000914686.HKD","FFEM","LU0516422952.EUR","LU1439103000.SGD","LU1718418525.SGD","LU0048580855.USD","LU0128522157.USD","LU0235996351.USD","SG9999000418.SGD","LDEM","TCHmain","LU0456842615.SGD","LU0819121731.USD","BK1237","LU0228659784.USD","LU1770036033.HKD","IE0008369823.USD","LU1282649810.SGD","ODDS","LU0029874905.USD","LU1048588211.SGD","LU1675838814.USD","LU1733274390.USD","BK4588","HTCD.SI","LU0918141887.USD","LU1282648689.USD","BK1517","LU0173614495.USD","LU0348784397.USD","LU1226288170.HKD","01112","LU0985320562.USD","SG9999002828.SGD","LU0203345920.USD","LU2097828714.EUR","LU0396098781.USD","LU0577902611.USD","09115","LU0823041008.USD","SG9999001846.SGD","LU0259732245.USD","83115","IE0009570106.USD","LU0128522744.USD","LU0417516738.SGD","LU2279701549.SGD","LU0261950983.USD","SG9999014898.SGD","AIPO","LU2778985437.USD","LU0192582467.USD","IE00B0169N27.USD","LU1282651121.HKD","IE00B8HQ1Z84.USD","BK1597","LU1211504680.USD","LU0320764755.SGD","LU0823426480.USD","LU2351347302.SGD","LU2125910849.SGD","HHImain","LU0823426308.USD","LU2045819591.USD","01888","LU0143863784.USD","BK1609","LU1282649067.USD","SG9999015978.USD","IE00B031HY20.USD","IE00B031HW06.USD","LU0880133367.SGD","BK1170","LU0828237940.HKD","LU0456846285.SGD","SG9999007991.SGD","LU1196710351.USD","HK0000352382.USD","LU1226287792.SGD","SG9999018857.SGD","LU1504937902.USD","LU0417516902.SGD","LU0543330566.HKD","LU2462611646.USD","LU1785774172.SGD","82800","09969","LU1568876335.HKD","HK0000151867.HKD","XSOE","LU2177674079.SGD","LU1196710864.SGD","LU1224444064.USD","HSI","LU0543330483.HKD","LU0264606111.USD","LU1224709979.USD","EMC","LU0165289439.USD","LU0531971595.HKD","LU0577902371.SGD","LU0251144936.SGD","LU1064130708.USD","KCAI","LU0329678337.USD","SG9999014674.SGD","LU0791591158.USD","LU1883866441.USD","LU0348827113.USD","SG9999001093.SGD","LU2251237306.USD","LU1196710195.USD","LU0608807946.USD","LU1770034418.SGD","LU0320764243.SGD","LU1568876251.USD","LU0261947096.USD","LU2257852520.SGD","LU1769817096.USD","LU0862451837.USD","SG9999014906.USD","LU0605514214.HKD","LU0080751232.USD","LU2125910500.SGD","LU1880383366.USD","LU1719994722.HKD","LU0823040885.USD","IE00B5MMRT66.SGD","LU1974910355.USD","LU0784639295.USD","LU0640798160.USD","LU1044876610.USD","LU1951186391.HKD","LU2152927971.USD","IE00B543WZ88.USD","LU0359202008.SGD","LU1188198961.HKD","LU0634319403.HKD","LU0540923850.HKD","02833","LU0181495838.USD","BK1095","LU0164880469.USD","LU1152091168.USD","LU0878005551.USD","LU0072462343.USD","IE00BZ08YT58.USD","LU1115378108.SGD","LU0441854154.USD","LU2097828557.USD","SG9999004220.SGD","HK0001040143.USD","LU0608807433.USD","LU0163747925.USD","03419","LU0823038988.USD","LU0329678170.USD","LU0862451753.SGD","LU2265009873.SGD","HK0000320223.HKD","LU0051755006.USD","LU0345769631.USD","LU0359201612.USD","LU1044874839.SGD","LU2023250504.SGD","02800","07300","LU0327786744.USD","LU0607220059.USD","LU0348825331.USD","00700","BK1502","LU0254981946.USD","LU0577902298.EUR","LU2148510915.USD","LU0228367735.SGD","LU1804176565.USD","LU1235295612.USD","IE0032431581.USD","HSImain","LU0823413660.USD","LU0823039010.USD","LU1808992512.USD","TCHI","LU0501845795.SGD","LU0326950275.SGD","LU0449515922.USD","LU1960683339.HKD","BK1608","LU2449936058.SGD","LU0370786039.SGD","LU1993786604.SGD","LU0588546209.SGD","SG9999003461.SGD","KWEB","LU0868486357.SGD","LU0873338254.USD","SG9999015945.SGD","LU2476274720.SGD","LU0672654166.SGD","LU1655091459.SGD","LU1807302812.USD","LU0577902454.USD","GB00BDT5M118.USD","LU0067412154.USD","LU1814569148.SGD","BK1589","IE00BF5LJ272.USD","LU2247934214.USD","LU0011963245.USD","HK0000914660.USD","LU2488822045.USD","03115","LU0269904917.USD","LU1813983027.USD","LU0314109678.HKD","LU1629966141.USD","LU1226288097.SGD","LU0359201885.HKD","LU0211331839.USD","BK1531","LU1880383440.USD","LU2929501877.USD","LU2097828631.EUR","VXUS","LU0117844026.USD","LU2051468812.USD","LU2317271919.USD","IE00B29SXG58.USD","LU0203347892.USD","LU0611395673.USD","BK1506","SGXZ90724238.SGD","159938","LU0651947912.USD","LU0169518387.USD","LU0188438112.USD","LU0315178854.USD","BK1574","LU0502904849.HKD","BK1526","LU0106959298.USD","LU0516422440.USD","IE00BQXX3D17.EUR","LU0052750758.USD","LU0823397285.USD","AGIX","LU0140636845.USD","LU0871576103.HKD","LU0048597586.USD","LU0651946864.USD","ARTY","LU0127658192.USD","LU1868837722.USD","LU2226246903.HKD","07500","LU0593848301.USD","SG9999001069.SGD","SG9999001903.USD","LU2237443978.SGD","LU1303224171.USD","LU0348735423.USD","LU0431992006.USD","LU1366334578.USD","LU0348783233.USD","LU1048596156.SGD","LU0117841782.USD","LU2187417386.USD","LU1810669033.SGD","LU0890818403.SGD","LU0791590937.USD","LU0588545904.SGD","LU0211977185.USD","LU1282649141.HKD","03037","LU0797268264.HKD","LU0572944931.SGD","BK1618","LU0210533765.USD","LU1226287529.USD","JADE","LU0289960550.SGD","LU0143863198.USD","LU0541501648.USD","IE00B8L5B284.USD","LU2237443465.HKD","LU0516423174.USD","SG9999001226.SGD","IE0001KFT4U8.USD","IE00B0JY6N72.USD","IE00B3M56506.USD","LU2293587155.HKD","LU0107464264.USD","BK1521","LU3227948356.SGD","LU0737861772.HKD","LU0210526637.USD","LU2362540622.SGD","SG9999014914.USD","SG9999017495.SGD","LU0348805143.USD","HK0001040168.HKD","SG9999000459.SGD","SG9999001689.USD","LU0345775950.USD","LU0106259558.USD","LU0972618739.USD","IE0034224299.USD","LU1961090484.USD","LU1868837565.USD","LU2097828474.EUR","LU0531970944.HKD","LU0589944569.HKD","LU1102505762.USD","LU0572940350.SGD","LU1917777945.USD","LU0210527791.USD","LU1064131003.USD","LU1105468828.SGD","LU0049112450.USD","LU1046422090.SGD","LU2087589342.USD","IE00BQXX3F31.USD","513600","LU0516423091.SGD","LU0828237510.HKD","LU2237443549.SGD","LU1242518931.SGD","LU1439102457.SGD","SGXZ99366536.SGD","LU0516422366.SGD","LU0469268626.HKD","LU0650527681.SGD","LU0819123356.HKD","LU2251237488.HKD","LU0043850808.USD","LU1981816686.USD","LU1734074674.USD","LU0633140727.USD","SG9999015952.SGD","LU2476274308.USD","LU1642822792.SGD","LU1688375341.USD","MCHS","LU2008162690.USD","LU1152091754.HKD","LU0348814723.USD","LU0633140560.USD","LU1044875133.USD","LU2106854487.HKD","MHImain","IE0032834883.USD","LU0831103253.SGD","LU0463099449.HKD","LU0084288322.USD","LU0918141705.HKD","LU0499858438.USD","BK1161","LU0149534421.HKD","AAXJ","LU0231483743.USD","LU2362541273.HKD","LU0214875030.USD","LU0878004406.USD","LU0708995583.HKD","LU0737861699.HKD","VTHR","LU2399975544.HKD","LU1316542783.SGD","LU0039217434.USD","LU0348783662.USD","LU0499858602.USD","SG9999000327.SGD","LU0979878070.USD","SG9999018865.SGD","LU0061477393.USD","BK1615","LU1242518857.USD","HK0000352291.HKD","SGXZ51526630.SGD","LU0029875118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133721592","title":"Biopharma Stocks Continue to Rally in Early Trading Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1133721592","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133721592?lang=en_us&edition=fundamental","pubTime":"2026-07-06 11:00","pubTimestamp":1783306840,"startTime":"0","endTime":"0","summary":"Shares within the biopharmaceutical sector maintained their upward momentum during the morning session.At the time of writing, SBP GROUP (ASX: 01177) shares had advanced by 10.76% to HK$5.25.INNOCARE...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","IBBQ","BK1161","IE00BZ08YR35.GBP","BK1521","159992","BK1589","IE00BZ08YS42.EUR","HK0000165453.HKD","688428","BK1191","06978","BK1574","BK0239","IE00BZ08YT58.USD","09969","BK1515","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131894691","title":"Innovative Drug Sector Maintains Upward Momentum on Favorable Regulatory Developments and Accelerating Internationalization","url":"https://stock-news.laohu8.com/highlight/detail?id=1131894691","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131894691?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:10","pubTimestamp":1783303836,"startTime":"0","endTime":"0","summary":"The innovative drug concept continued its upward trend in Hong Kong trading.Innocare (09969) rose 7.95% to HK$14.12, SBP GROUP (01177) gained 7.38% to HK$5.09, and KEYMED BIO-B (02162) advanced 7.01%...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287875.USD","LU1226287529.USD","BK1191","LU0501845795.SGD","BK1161","LU1951186391.HKD","VXUS","BK4585","IE00B543WZ88.USD","LU1008478684.HKD","LU0326950275.SGD","LU1960683339.HKD","LU2097828631.EUR","IE00B031HY20.USD","LU0072913022.USD","LU1993786604.SGD","LU2328871848.SGD","LU2242644610.SGD","LU1152091168.USD","LU0880133367.SGD","159992","IE00BZ08YT58.USD","IE0008368742.USD","LU0455707207.USD","LU2097828557.USD","SG9999004220.SGD","01801","KCAI","LU1226288253.USD","BK1521","LU0315179316.USD","LU1969619763.USD","LU2097828805.USD","IBBQ","IE0008369823.USD","01177","KURE","LU1807302812.USD","BK1574","BK1587","BK4588","HK0000165453.HKD","LU0067412154.USD","LU0502904849.HKD","BK1583","BK1589","LU1152091754.HKD","LU1226287792.SGD","LU2097828474.EUR","LU1226288170.HKD","MEDX","02162","06978","LU1328277881.USD","LU2488822045.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU0140636845.USD","BK1515","LU2039709279.SGD","09969","01093","LU1813983027.USD","LU0314109678.HKD","LU2097828714.EUR","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117757580","title":"Innocare's Stock Surges Over 9% as First Patient Dosed with Novel In-house Developed CDH17-Targeting ADC Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1117757580","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117757580?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:00","pubTimestamp":1783303238,"startTime":"0","endTime":"0","summary":"Shares of Innocare (09969) surged more than 9% during intraday trading. At the time of writing, the stock was up 6.42% to HK$13.92, with a turnover of HK$542.69 million. On July 6th, the company...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NETL","159992","BK4080","BK1574","IBBQ","ADC","BK0239","09969","MEDX","BK1161","06978","688428","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120897847","title":"Movement Alert｜InnoCare Pharma Rises 6.65% in Regular Trading, Self-Developed ADC Drug ICP-B208 Completes First Patient Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=1120897847","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120897847?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:00","pubTimestamp":1783303230,"startTime":"0","endTime":"0","summary":"On July 6, InnoCare Pharma (09969.HK) rose 6.65% in regular trading, trading at HK$14.03/share, with turnover of HK$72.80 million.On the news front, InnoCare Pharma announced that its self-developed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149233574","title":"Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149233574","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149233574?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:58","pubTimestamp":1783303082,"startTime":"0","endTime":"0","summary":"Hong Kong innovative drug stocks jumped in market trading. $HAIXI PHARMA(02637)$, $INNOCARE(09969)$ up 7%; $KEYMED BIO-B(02162)$ up 5%; $REMEGEN(09995)$, $INNOVENT BIO(01801)$, $SIMCERE PHARMA(02096)$ up 4%; $LEPU BIO(02157)$ up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","09969","02157","SOXL","02637","01801","02162","09995"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0484},{"period":"1month","weight":0.068},{"period":"3month","weight":0.0585},{"period":"6month","weight":0.1137},{"period":"1year","weight":-0.1893},{"period":"ytd","weight":0.1626}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":0.0607},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0336},{"period":"1year","weight":0.0234},{"period":"ytd","weight":0.0015}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.102464},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.059233},{"month":6,"riseRate":0.857143,"avgChangeRate":0.113731},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05509},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.063466},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"INNOCARE","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOCARE(09969) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOCARE,09969,INNOCARE股票,INNOCARE股票老虎,INNOCARE股票老虎国际,INNOCARE行情,INNOCARE股票行情,INNOCARE股价,INNOCARE股市,INNOCARE股票价格,INNOCARE股票交易,INNOCARE股票购买,INNOCARE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOCARE(09969) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}